Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction PART 05: Disease overview PART 06: Market overview • Five forces analysis PART 07: Pipeline landscape PART 08: Market segmentation by disease type • Acute GVHD PART 09: Geographical segmentation • GVHD treatment market in Americas • GVHD treatment market in EMEA • GVHD treatment market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Inorganic growth strategies • Newer applications of bone marrow transplant • Growing focus toward the use of biologics PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • Bristol-Myers Squibb • F. Hoffmann-La Roche • Novartis • Pfizer • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Mechanism of GVHD Exhibit 02: Global GVHD treatment market growth promoters Exhibit 03: Major acute GVHD symptoms Exhibit 04: Major chronic GVHD symptoms Exhibit 05: Global GVHD treatment market 2016-2021 ($ millions) Exhibit 06: Opportunity analysis in global GVHD treatment market Exhibit 07: Five forces analysis Exhibit 08: Pipeline molecules as per vendors Exhibit 09: Key clinical trials Exhibit 10: Segmentation of global GVHD treatment market by disease type 2016 Exhibit 11: Symptoms in acute GVHD Exhibit 12: Global acute GVHD treatment market 2016-2021 ($ millions) Exhibit 13: Symptoms in chronic GVHD Exhibit 14: Global chronic GVHD treatment market 2016-2021 ($ millions) Exhibit 15: Segmentation of global GVHD treatment market by geography 2016 and 2021 Exhibit 16: Segmentation of global GVHD treatment market revenue by geography 2016-2021 ($ millions) Exhibit 17: Market scenario in Americas Exhibit 18: GVHD treatment market in Americas 2016-2021 ($ millions) Exhibit 19: Market scenario in EMEA Exhibit 20: GVHD treatment market in EMEA 2016-2021 ($ millions) Exhibit 21: Market scenario in APAC Exhibit 22: GVHD treatment market in APAC 2016-2021 ($ millions) Exhibit 23: Percentage distribution of transplants by organ in US (1988-2016) Exhibit 24: Various major types of cancers managed by bone marrow transplant Exhibit 25: Various off-label drugs used in the management of GVHD Exhibit 26: Various symptoms and disorders associated with GVHD Exhibit 27: Legal and ethical issues in countries Exhibit 28: Inorganic growth strategies Exhibit 29: Newer applications of bone marrow transplant Exhibit 30: Competitive structure analysis of global GVHD treatment market 2016 Exhibit 31: Market penetration of various GVHD drugs manufacturers worldwide 2016 Exhibit 32: Strategic success factors of companies in global GVHD treatment market Exhibit 33: Bristol-Myers Squibb: Key highlights Exhibit 34: Bristol-Myers Squibb: Strength assessment Exhibit 35: Bristol-Myers Squibb: Strategy assessment Exhibit 36: Bristol-Myers Squibb: Opportunity assessment Exhibit 37: F. Hoffmann-La Roche: Key highlights Exhibit 38: F. Hoffmann-La Roche: Strength assessment Exhibit 39: F. Hoffmann-La Roche: Strategy assessment Exhibit 40: F. Hoffmann-La Roche: Opportunity assessment Exhibit 41: Novartis: Key highlights Exhibit 42: Novartis: Strength assessment Exhibit 43: Novartis: Strategy assessment Exhibit 44: Novartis: Opportunity assessment Exhibit 45: Pfizer: Key highlights Exhibit 46: Pfizer: Strength assessment Exhibit 47: Pfizer: Strategy assessment Exhibit 48: Pfizer: Opportunity assessment

Bristol-Myers Squibb, Novartis, Pfizer, F. Hoffmann-La Roche, bbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.